HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Population versus hospital controls in the assessment of dietary intake of isoflavone for case-control studies on cancers in China.

Abstract
To assess dietary isoflavone intake between population and hospital outpatient controls and examine if cancer risks estimated for isoflavone using hospital outpatient controls would be different from those using population controls. Three parallel case-control studies on leukemia, breast, and colorectal cancers in China in 2009-2010 were conducted, using population and hospital outpatient controls to separately match 560 incident cases at a 1:1 ratio. A validated food frequency questionnaire was administered by face-to-face interview. Conditional logistic regression analysis was used to estimate odds ratios (ORs) and 95% confidence intervals (CIs). The 2 control groups had closely similar distributions of dietary isoflavone intake. Risk estimates for breast cancers were adjusted ORs (95% CI) of 0.39 (0.23-0.66) and 0.31 (0.18-0.55) for daidzein, 0.35 (0.20-0.61) and 0.28 (0.16-0.52) for genistein, 0.66 (0.41-1.08) and 0.53 (0.32-0.88) for glycitein, and 0.53 (0.33-0.85) and 0.43 (0.26-0.71) for total isoflavone using hospital outpatient and population controls respectively. The study found that hospital outpatient controls were comparable to population controls in measured dietary intake of isoflavone in the Chinese hospital setting.
AuthorsLin Li, Min Zhang, C D'Arcy J Holman
JournalNutrition and cancer (Nutr Cancer) Vol. 65 Issue 3 Pg. 390-7 ( 2013) ISSN: 1532-7914 [Electronic] United States
PMID23530638 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Isoflavones
  • daidzein
  • glycitein
  • Genistein
Topics
  • Adult
  • Aged
  • Breast Neoplasms (epidemiology)
  • Case-Control Studies
  • China (epidemiology)
  • Colorectal Neoplasms (epidemiology)
  • Diet
  • Female
  • Genistein (administration & dosage)
  • Humans
  • Isoflavones (administration & dosage)
  • Leukemia (epidemiology)
  • Male
  • Middle Aged
  • Neoplasms (epidemiology)
  • Odds Ratio
  • Outpatient Clinics, Hospital
  • Risk Factors

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: